Related Experiment Video
Updated: Sep 4, 2025
06:49
Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
11.7K
Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control
Javier Gandasegui1, Chukwuemeka Onwuchekwa1, Alejandro J Krolewiecki2
1Barcelona Institute for Global Health, Hospital Clínic Universitat de Barcelona, Barcelona, Spain.
The Lancet. Infectious Diseases
|July 19, 2022
Summary
Strongyloidiasis control requires integrated strategies with soil-transmitted helminths (STH). Developing efficient mass drug administration programs using ivermectin and albendazole, alongside improved diagnostics and resistance monitoring, is crucial for global reduction.
Area of Science:
- Global Health
- Infectious Diseases
- Parasitology
Background:
- The World Health Organization (WHO) has prioritized strongyloidiasis control alongside soil-transmitted helminths (STH) in its 2021-30 roadmap.
- Preventive chemotherapy using ivermectin is a key strategy for targeting *Strongyloides stercoralis*.
Purpose of the Study:
- To discuss challenges and opportunities for developing an efficient control program for strongyloidiasis, concurrent with STH control.
- To highlight the need for defined prevalence thresholds, target populations, and optimal dosing for *S. stercoralis* preventive chemotherapy.
- To explore the benefits of a fixed-dose coformulation of ivermectin and albendazole.
Main Methods:
- Review of current strategies and challenges in strongyloidiasis and STH control.
- Discussion of diagnostic improvements and multispecies diagnostic needs.
- Consideration of ivermectin resistance and the role of genome-wide approaches.
Main Results:
- Combination treatment with albendazole and ivermectin can enhance mass drug administration efficiency.
- Improvements in diagnostics are essential for effective targeting and monitoring of *S. stercoralis* infections.
- Ivermectin resistance poses a credible risk, necessitating research into its characterization and prevention.
Conclusions:
- An integrated approach is needed to control strongyloidiasis and STH globally.
- Further research into diagnostics, drug formulations, and resistance mechanisms is vital.
- Overcoming these challenges will reduce the global burden of strongyloidiasis.
Related Concept Videos
01:17Drugs for Treatment of Diarrhea-Predominant IBS
283
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
283
01:29Drugs for Treatment of Ulcerative Colitis in IBD
230
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
230
01:21Drugs for Treatment of Constipation-Predominant IBS
311
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
311
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
260
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
260
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
197
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
197
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
198
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
198